Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8263355 | 0.92 | REN (0.43) | GPR119USP30RENCYP3A4 | |
| SCHEMBL8262749 | 0.92 | REN (0.43) | GPR119RENCYP3A4 | |
| SCHEMBL13490820 | 0.92 | USP30 (0.41) | GPR119MEN1KMT2AUSP30REN | |
| SCHEMBL8265339 | 0.90 | CYP3A4 (0.39) | GPR119MGAT2DGAT2MEN1KMT2A | |
| SCHEMBL8263343 | 0.89 | CYP3A4 (0.44) | MGAT2DGAT2MEN1KMT2AREN | |
| SCHEMBL8263338 | 0.89 | REN (0.41) | GPR119MGAT2DGAT2MEN1KMT2A | |
| SCHEMBL8265157 | 0.89 | SLC2A1 (0.43) | GPR119MGAT2DGAT2MEN1KMT2A | |
| SCHEMBL8264237 | 0.89 | REN (0.45) | USP30RENCYP3A4 | |
| SCHEMBL13490822 | 0.88 | USP30 (0.40) | GPR119MGAT2DGAT2USP30REN | |
| SCHEMBL8264159 | 0.88 | GPR119 (0.42) | GPR119MGAT2DGAT2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | GPR119 1021/4885MGAT2 2203/4885DGAT2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.